<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31062226</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1525-1497</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of general internal medicine</Title>
          <ISOAbbreviation>J Gen Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GABA<sub>B</sub>R-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>1658</StartPage>
          <EndPage>1661</EndPage>
          <MedlinePgn>1658-1661</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11606-019-05040-4</ELocationID>
        <Abstract>
          <AbstractText>We report the case of a 55-year-old male who presented with several weeks of seizures, agitation, progressive confusion, and receptive aphasia. CSF showed a monocytic pleocytosis and tested positive for GABA<sub>B</sub> receptor autoantibodies. Pathological examination of an excisional mediastinal lymph node biopsy showed thymic small cell carcinoma, supporting a diagnosis of paraneoplastic limbic encephalitis (PLE). PLE is a subtype of limbic encephalitis and is associated with an array of autoantibodies. Neurologic symptoms related to PLE may precede the detection of the primary cancer. Recognition of the constellation of clinical features of limbic encephalitis should prompt initiation of diagnostic testing for this condition as well as evaluation for an underlying malignancy. A review of the literature reveals that this is the first case report of a patient with thymic small cell cancer presenting with PLE.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bordin-Wosk</LastName>
            <ForeName>Talya</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hospital Medicine, Department of Medicine, University of California, San Diego, San Diego, CA, USA. tbordinwosk@ucsd.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Sandip Pravin</ForeName>
            <Initials>SP</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology- Oncology, Department of Medicine, UC San Diego, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Horman</LastName>
            <ForeName>Sarah F</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hospital Medicine, Department of Medicine, University of California, San Diego, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Gen Intern Med</MedlineTA>
        <NlmUniqueID>8605834</NlmUniqueID>
        <ISSNLinking>0884-8734</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018080">Receptors, GABA-B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>56-12-2</RegistryNumber>
          <NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018288" MajorTopicYN="N">Carcinoma, Small Cell</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018080" MajorTopicYN="N">Receptors, GABA-B</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013953" MajorTopicYN="N">Thymus Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">GABABR antibody</Keyword>
        <Keyword MajorTopicYN="Y">limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="Y">paraneoplastic</Keyword>
        <Keyword MajorTopicYN="Y">thymic small cell carcinoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they do not have a conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31062226</ArticleId>
        <ArticleId IdType="pmc">PMC6667585</ArticleId>
        <ArticleId IdType="doi">10.1007/s11606-019-05040-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s11606-019-05040-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lee BY, Newberg AB, Liebeskind DS, Kung J, Alavi A. FDG-PET Findings in patients with suspected encephalitis. Clin Nucl Med. 2004;29(10):620–5. doi: 10.1097/00003072-200410000-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00003072-200410000-00004</ArticleId>
            <ArticleId IdType="pubmed">15365433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solnes LB, Jones KM, Rowe SP, et al.  Diagnostic value of 18 F-FDG PET/CT versus MRI in the setting of antibody specific autoimmune encephalitis. J Nucl Med. 2017;58(8):1307–1313. doi: 10.2967/jnumed.116.184333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2967/jnumed.116.184333</ArticleId>
            <ArticleId IdType="pmc">PMC6944181</ArticleId>
            <ArticleId IdType="pubmed">28209905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quartuccio N, Caobelli F, Evangelista L, et al.  The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature. J Neuroimmunol. 2015;284:44–48. doi: 10.1016/j.jneuroim.2015.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2015.05.002</ArticleId>
            <ArticleId IdType="pubmed">26025057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27(6):489–495. doi: 10.1097/CCO.0000000000000222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0000000000000222</ArticleId>
            <ArticleId IdType="pmc">PMC4640358</ArticleId>
            <ArticleId IdType="pubmed">26335665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jammoul A, Li Y, Rae-Grant A. Autonantibody-mediated encephalitis: Not just paraneoplastic, not just limbic, and not untreatable. Clev Clin J Med. 2016;83(1):43–53. doi: 10.3949/ccjm.83a.14112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3949/ccjm.83a.14112</ArticleId>
            <ArticleId IdType="pubmed">26760522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E, Lai M, Peng X, et al.  Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67–76. doi: 10.1016/S1474-4422(09)70324-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70324-2</ArticleId>
            <ArticleId IdType="pmc">PMC2824142</ArticleId>
            <ArticleId IdType="pubmed">19962348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76(9):795–800. doi: 10.1212/WNL.0b013e31820e7b8d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31820e7b8d</ArticleId>
            <ArticleId IdType="pmc">PMC3053332</ArticleId>
            <ArticleId IdType="pubmed">21357831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R, Titulaer MJ, Sabater L, et al.  Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81(17):1500–6. doi: 10.1212/WNL.0b013e3182a9585f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182a9585f</ArticleId>
            <ArticleId IdType="pmc">PMC3888170</ArticleId>
            <ArticleId IdType="pubmed">24068784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dogan OM, Deuretzbacher D, Haensch CA, et al.  Limbic encephalitis due to GABA b and MPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry. 2015;86:965–972. doi: 10.1136/jnnp-2014-308814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2014-308814</ArticleId>
            <ArticleId IdType="pubmed">25300449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan HZ, Ren HT, Yang XZ, et al.  Limbic encephalitis associated with anti-γ-aminobutyric acid B receptor antibodies: a case series from China. China Med J. 2015;128(22):3023–8. doi: 10.4103/0366-6999.168989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0366-6999.168989</ArticleId>
            <ArticleId IdType="pmc">PMC4795264</ArticleId>
            <ArticleId IdType="pubmed">26608981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, et al.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain. 2000;123(7):1481–1494. doi: 10.1093/brain/123.7.1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/123.7.1481</ArticleId>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexopoulos H, Dagklis IE, Akrivou S, Bostantjopoulou S, Dalackas MC. Autoimmune encephalitis with GABAB antibodies, thymoma, and GABAB receptor thymic expression. Neurol Neuroimmino Neuroinflamm. 2014;1(4):e39. doi: 10.1212/NXI.0000000000000039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000039</ArticleId>
            <ArticleId IdType="pmc">PMC4215391</ArticleId>
            <ArticleId IdType="pubmed">25364773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao JC, Hassan M, Phan A, et al.  One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):306–372. doi: 10.1200/JCO.2007.15.4377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.15.4377</ArticleId>
            <ArticleId IdType="pubmed">18565894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye L, Want W, Ospina NS, et al.  Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: a single-center study, systemic review and meta-analysis. Clin Endocrinol. 2017;87(6):706–716. doi: 10.1111/cen.13480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.13480</ArticleId>
            <ArticleId IdType="pubmed">28940393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan JL, Weksler B. Neuroendocrine tumors of the thymus: analysis of factors affecting survival in 254 patients. Ann Thorac Surg. 2017;103(3):935–939. doi: 10.1016/j.athoracsur.2016.07.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.athoracsur.2016.07.050</ArticleId>
            <ArticleId IdType="pubmed">27720367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World health organization classification of tumours. tathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. pp. 188–95.</Citation>
        </Reference>
        <Reference>
          <Citation>Fletcher CD.  Diagnostic histopathology of tumors. 2. Edinburgh: Churchill Livingstone; 2000. pp. 1276–1295.</Citation>
        </Reference>
        <Reference>
          <Citation>Cai YC, Banner B, Glickman J, Odze RD. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol. 2001;32:1087–1093. doi: 10.1053/hupa.2001.28245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/hupa.2001.28245</ArticleId>
            <ArticleId IdType="pubmed">11679943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folpe AL, Gown AM, Lamps LW, et al.  Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol. 1999;12:5–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9950155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36(5):415–420. doi: 10.1046/j.1365-2559.2000.00890.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2559.2000.00890.x</ArticleId>
            <ArticleId IdType="pubmed">10792482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asirvatham JR, Esposito MJ, Bhuiya TA. Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma. Appl Immunohistochem Mol Morphol. 2014;22(5):372–6. doi: 10.1097/PAI.0b013e318297cdb5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAI.0b013e318297cdb5</ArticleId>
            <ArticleId IdType="pubmed">23958552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weissferdt A, Moran CA. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am J Surg Pathol. 2011;35(9):1305–10. doi: 10.1097/PAS.0b013e3182260735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e3182260735</ArticleId>
            <ArticleId IdType="pubmed">21836478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul ML, Kleinig TJ. Therapy of paraneoplastic disorders of the CNS. Expert Rev Neurother. 2015;15(2):187–193. doi: 10.1586/14737175.2015.1000310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737175.2015.1000310</ArticleId>
            <ArticleId IdType="pubmed">25614953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster  The diagnosis and treatment of Autoimmune encephalitis. J Clin Neurol. 2016;12(1):1–13. doi: 10.3988/jcn.2016.12.1.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2016.12.1.1</ArticleId>
            <ArticleId IdType="pmc">PMC4712273</ArticleId>
            <ArticleId IdType="pubmed">26754777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeshokumar AK, Gordon-Lipkin E, Arenivas A, et al.  Neurobehavioral outcomes in autoimmune encephalitis. J Neuroimmunol. 2017;213:8–14. doi: 10.1016/j.jneuroim.2017.08.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2017.08.010</ArticleId>
            <ArticleId IdType="pubmed">28889962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, McCracken L, Gabilondo I, et al.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165. doi: 10.1016/S1474-4422(12)70310-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(12)70310-1</ArticleId>
            <ArticleId IdType="pmc">PMC3563251</ArticleId>
            <ArticleId IdType="pubmed">23290630</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31062226</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1525-1497</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of general internal medicine</Title>
          <ISOAbbreviation>J Gen Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GABA<sub>B</sub>R-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>1658</StartPage>
          <EndPage>1661</EndPage>
          <MedlinePgn>1658-1661</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11606-019-05040-4</ELocationID>
        <Abstract>
          <AbstractText>We report the case of a 55-year-old male who presented with several weeks of seizures, agitation, progressive confusion, and receptive aphasia. CSF showed a monocytic pleocytosis and tested positive for GABA<sub>B</sub> receptor autoantibodies. Pathological examination of an excisional mediastinal lymph node biopsy showed thymic small cell carcinoma, supporting a diagnosis of paraneoplastic limbic encephalitis (PLE). PLE is a subtype of limbic encephalitis and is associated with an array of autoantibodies. Neurologic symptoms related to PLE may precede the detection of the primary cancer. Recognition of the constellation of clinical features of limbic encephalitis should prompt initiation of diagnostic testing for this condition as well as evaluation for an underlying malignancy. A review of the literature reveals that this is the first case report of a patient with thymic small cell cancer presenting with PLE.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bordin-Wosk</LastName>
            <ForeName>Talya</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hospital Medicine, Department of Medicine, University of California, San Diego, San Diego, CA, USA. tbordinwosk@ucsd.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Sandip Pravin</ForeName>
            <Initials>SP</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology- Oncology, Department of Medicine, UC San Diego, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Horman</LastName>
            <ForeName>Sarah F</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hospital Medicine, Department of Medicine, University of California, San Diego, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Gen Intern Med</MedlineTA>
        <NlmUniqueID>8605834</NlmUniqueID>
        <ISSNLinking>0884-8734</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018080">Receptors, GABA-B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>56-12-2</RegistryNumber>
          <NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018288" MajorTopicYN="N">Carcinoma, Small Cell</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018080" MajorTopicYN="N">Receptors, GABA-B</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013953" MajorTopicYN="N">Thymus Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">GABABR antibody</Keyword>
        <Keyword MajorTopicYN="Y">limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="Y">paraneoplastic</Keyword>
        <Keyword MajorTopicYN="Y">thymic small cell carcinoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they do not have a conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31062226</ArticleId>
        <ArticleId IdType="pmc">PMC6667585</ArticleId>
        <ArticleId IdType="doi">10.1007/s11606-019-05040-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s11606-019-05040-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lee BY, Newberg AB, Liebeskind DS, Kung J, Alavi A. FDG-PET Findings in patients with suspected encephalitis. Clin Nucl Med. 2004;29(10):620–5. doi: 10.1097/00003072-200410000-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00003072-200410000-00004</ArticleId>
            <ArticleId IdType="pubmed">15365433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solnes LB, Jones KM, Rowe SP, et al.  Diagnostic value of 18 F-FDG PET/CT versus MRI in the setting of antibody specific autoimmune encephalitis. J Nucl Med. 2017;58(8):1307–1313. doi: 10.2967/jnumed.116.184333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2967/jnumed.116.184333</ArticleId>
            <ArticleId IdType="pmc">PMC6944181</ArticleId>
            <ArticleId IdType="pubmed">28209905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quartuccio N, Caobelli F, Evangelista L, et al.  The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature. J Neuroimmunol. 2015;284:44–48. doi: 10.1016/j.jneuroim.2015.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2015.05.002</ArticleId>
            <ArticleId IdType="pubmed">26025057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27(6):489–495. doi: 10.1097/CCO.0000000000000222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0000000000000222</ArticleId>
            <ArticleId IdType="pmc">PMC4640358</ArticleId>
            <ArticleId IdType="pubmed">26335665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jammoul A, Li Y, Rae-Grant A. Autonantibody-mediated encephalitis: Not just paraneoplastic, not just limbic, and not untreatable. Clev Clin J Med. 2016;83(1):43–53. doi: 10.3949/ccjm.83a.14112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3949/ccjm.83a.14112</ArticleId>
            <ArticleId IdType="pubmed">26760522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E, Lai M, Peng X, et al.  Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67–76. doi: 10.1016/S1474-4422(09)70324-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70324-2</ArticleId>
            <ArticleId IdType="pmc">PMC2824142</ArticleId>
            <ArticleId IdType="pubmed">19962348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76(9):795–800. doi: 10.1212/WNL.0b013e31820e7b8d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31820e7b8d</ArticleId>
            <ArticleId IdType="pmc">PMC3053332</ArticleId>
            <ArticleId IdType="pubmed">21357831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R, Titulaer MJ, Sabater L, et al.  Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81(17):1500–6. doi: 10.1212/WNL.0b013e3182a9585f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182a9585f</ArticleId>
            <ArticleId IdType="pmc">PMC3888170</ArticleId>
            <ArticleId IdType="pubmed">24068784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dogan OM, Deuretzbacher D, Haensch CA, et al.  Limbic encephalitis due to GABA b and MPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry. 2015;86:965–972. doi: 10.1136/jnnp-2014-308814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2014-308814</ArticleId>
            <ArticleId IdType="pubmed">25300449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan HZ, Ren HT, Yang XZ, et al.  Limbic encephalitis associated with anti-γ-aminobutyric acid B receptor antibodies: a case series from China. China Med J. 2015;128(22):3023–8. doi: 10.4103/0366-6999.168989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0366-6999.168989</ArticleId>
            <ArticleId IdType="pmc">PMC4795264</ArticleId>
            <ArticleId IdType="pubmed">26608981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, et al.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain. 2000;123(7):1481–1494. doi: 10.1093/brain/123.7.1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/123.7.1481</ArticleId>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexopoulos H, Dagklis IE, Akrivou S, Bostantjopoulou S, Dalackas MC. Autoimmune encephalitis with GABAB antibodies, thymoma, and GABAB receptor thymic expression. Neurol Neuroimmino Neuroinflamm. 2014;1(4):e39. doi: 10.1212/NXI.0000000000000039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000039</ArticleId>
            <ArticleId IdType="pmc">PMC4215391</ArticleId>
            <ArticleId IdType="pubmed">25364773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao JC, Hassan M, Phan A, et al.  One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):306–372. doi: 10.1200/JCO.2007.15.4377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.15.4377</ArticleId>
            <ArticleId IdType="pubmed">18565894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye L, Want W, Ospina NS, et al.  Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: a single-center study, systemic review and meta-analysis. Clin Endocrinol. 2017;87(6):706–716. doi: 10.1111/cen.13480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.13480</ArticleId>
            <ArticleId IdType="pubmed">28940393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan JL, Weksler B. Neuroendocrine tumors of the thymus: analysis of factors affecting survival in 254 patients. Ann Thorac Surg. 2017;103(3):935–939. doi: 10.1016/j.athoracsur.2016.07.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.athoracsur.2016.07.050</ArticleId>
            <ArticleId IdType="pubmed">27720367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World health organization classification of tumours. tathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. pp. 188–95.</Citation>
        </Reference>
        <Reference>
          <Citation>Fletcher CD.  Diagnostic histopathology of tumors. 2. Edinburgh: Churchill Livingstone; 2000. pp. 1276–1295.</Citation>
        </Reference>
        <Reference>
          <Citation>Cai YC, Banner B, Glickman J, Odze RD. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol. 2001;32:1087–1093. doi: 10.1053/hupa.2001.28245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/hupa.2001.28245</ArticleId>
            <ArticleId IdType="pubmed">11679943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folpe AL, Gown AM, Lamps LW, et al.  Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol. 1999;12:5–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9950155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36(5):415–420. doi: 10.1046/j.1365-2559.2000.00890.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2559.2000.00890.x</ArticleId>
            <ArticleId IdType="pubmed">10792482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asirvatham JR, Esposito MJ, Bhuiya TA. Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma. Appl Immunohistochem Mol Morphol. 2014;22(5):372–6. doi: 10.1097/PAI.0b013e318297cdb5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAI.0b013e318297cdb5</ArticleId>
            <ArticleId IdType="pubmed">23958552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weissferdt A, Moran CA. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am J Surg Pathol. 2011;35(9):1305–10. doi: 10.1097/PAS.0b013e3182260735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e3182260735</ArticleId>
            <ArticleId IdType="pubmed">21836478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul ML, Kleinig TJ. Therapy of paraneoplastic disorders of the CNS. Expert Rev Neurother. 2015;15(2):187–193. doi: 10.1586/14737175.2015.1000310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737175.2015.1000310</ArticleId>
            <ArticleId IdType="pubmed">25614953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster  The diagnosis and treatment of Autoimmune encephalitis. J Clin Neurol. 2016;12(1):1–13. doi: 10.3988/jcn.2016.12.1.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2016.12.1.1</ArticleId>
            <ArticleId IdType="pmc">PMC4712273</ArticleId>
            <ArticleId IdType="pubmed">26754777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeshokumar AK, Gordon-Lipkin E, Arenivas A, et al.  Neurobehavioral outcomes in autoimmune encephalitis. J Neuroimmunol. 2017;213:8–14. doi: 10.1016/j.jneuroim.2017.08.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2017.08.010</ArticleId>
            <ArticleId IdType="pubmed">28889962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, McCracken L, Gabilondo I, et al.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165. doi: 10.1016/S1474-4422(12)70310-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(12)70310-1</ArticleId>
            <ArticleId IdType="pmc">PMC3563251</ArticleId>
            <ArticleId IdType="pubmed">23290630</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
